輝瑞藥廠(PFE.US)據報削數百個美國銷售職位
《路透》報道,美國輝瑞藥廠(PFE.US)表示,預期醫生及其他醫療服務供應商在新冠疫後減少與藥廠銷售人員面對面接觸,因此正在減少美國銷售員工。公司稱他們轉變爲更集中及創新的生物醫藥公司,並在更爲數碼化的世界改變與醫護專業人員的接觸方式。公司將就人力資源方面作出變動,確保擁有最正確專才及資源以符合公司改變中的需要。
公司沒有披露今次裁員數目。報道則引述消息指裁減職位涉及數百個,同時在其他領域創造新職位,數量爲削減職位數目約半。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.